Comparative Pharmacology
Head-to-head clinical analysis: FAVLYXA versus GANCICLOVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAVLYXA versus GANCICLOVIR.
FAVLYXA vs GANCICLOVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclic nucleoside phosphonate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRP) by competing with adenosine triphosphate (ATP). It incorporates into nascent viral RNA causing chain termination after incorporation of the first 1-2 nucleotides.
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
200 mg orally twice daily for 10 days.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
None Documented
None Documented
Clinical Note
moderateGanciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Valganciclovir."
Clinical Note
moderateGanciclovir + Mycophenolic acid
"The serum concentration of Mycophenolic acid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Mycophenolic acid
Terminal elimination half-life approximately 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 24 hours in severe impairment).
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for CrCl <70 mL/min
Primarily renal excretion of unchanged drug (approx. 85%) with biliary/fecal elimination accounting for the remainder (approx. 15%).
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Category C
Category D/X
Antiviral
Antiviral
"The serum concentration of Mycophenolic acid can be increased when it is combined with Valganciclovir."